Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:01:52 EDT Tue 07 May 2024
Enter Symbol
or Name
USA
CA



News for U:BCRX from 2023-05-08 to 2024-05-07 - 46 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-07 07:00U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2024-05-06 07:00U:BCRXNews ReleaseBioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-03 07:00U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-22 07:01U:BCRXNews ReleaseBioCryst to Report First Quarter 2024 Financial Results on May 6
2024-04-17 04:31U:BCRXNews ReleaseBioCryst Announces Approval of ORLADEYO(TM) (berotralstat) by the Brazilian Health Regulatory Agency
2024-04-03 07:00U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-25 16:01U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2024-03-05 07:02U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-26 07:00U:BCRXNews ReleaseBioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
2024-02-23 07:00U:BCRXNews ReleaseBioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO(TM) (berotralstat) Treatment
2024-02-21 16:02U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2024-02-19 07:55U:BCRXNews ReleaseBioCryst Launches ORLADEYO ‚ ® (berotralstat) in Italy
2024-02-12 07:01U:BCRXNews ReleaseBioCryst to Report Fourth Quarter 2023 Financial Results on February 26
2024-02-05 07:00U:BCRXNews ReleaseBioCryst to Present New ORLADEYO ‚ ® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
2024-02-02 07:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-05 16:01U:BCRXNews ReleaseBioCryst Announces Preliminary Full Year 2023 ORLADEYO ‚ ® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability
2024-01-03 16:02U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 07:01U:BCRXNews ReleaseBioCryst to Present at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-19 07:00U:BCRXNews ReleaseBioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO ‚ ® (berotralstat)
2023-12-05 16:02U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 07:00U:BCRXNews ReleaseBioCryst Announces Approval of ORLADEYO ‚ ® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina
2023-11-21 16:02U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2023-11-21 07:00U:BCRXNews ReleaseBioCryst Launches ORLADEYO ‚ ® ‚  (berotralstat) in Spain
2023-11-10 07:00U:BCRXNews ReleaseBioCryst Presents New Real-world Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-inhibitor Following Long-term Treatment with ORLADEYO ‚ ® (berotralstat)
2023-11-06 16:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-03 12:03U:BCRXNews ReleaseBioCryst R&D Day Highlights New Diversified Pipeline of First-in-Class/Best-in-Class Therapies with Five Programs Expected in Clinical Development in Next 24 Months
2023-11-03 12:00U:BCRXNews ReleaseBioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside ¢ € ™s Proprietary SCS Microinjector ‚ ®
2023-11-02 07:01U:BCRXNews ReleaseBioCryst Reports Third Quarter 2023 Financial Results and ‚  Provides Business Update
2023-10-27 07:00U:BCRXNews ReleaseBioCryst to Present New ORLADEYO ‚ ® (berotralstat) Data at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
2023-10-26 07:00U:BCRXNews ReleaseBioCryst Begins Enrollment in Proof-of-Concept Trial to Confirm Safe, Effective, Once-daily Dose of Oral Factor D Inhibitor, BCX10013
2023-10-20 07:00U:BCRXNews ReleaseBioCryst to Host R&D Day on November 3
2023-10-19 07:00U:BCRXNews ReleaseBioCryst to Report Third Quarter 2023 Financial Results on November 2
2023-10-04 07:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-18 07:00U:BCRXNews ReleaseINESSS Recommends Public Reimbursement for BioCryst ¢ € ™s ORLADEYO ‚ ® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Qu ƒ ©bec
2023-09-05 07:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-23 16:02U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conferences
2023-08-04 16:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 07:01U:BCRXNews ReleaseBioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-07-20 07:01U:BCRXNews ReleaseBioCryst to Report Second Quarter 2023 Financial Results on August 3
2023-07-19 07:00U:BCRXNews ReleaseBioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO ‚ ® (berotralstat) in Turkey
2023-07-17 07:00U:BCRXNews ReleaseBioCryst to Participate in the 2023 US HAEA National Summit
2023-07-06 07:00U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-06 07:01U:BCRXNews ReleaseBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-01 07:01U:BCRXNews ReleaseBioCryst to Present at Upcoming Investor Conference
2023-05-31 07:02U:BCRXNews ReleaseBioCryst to Present New ORLADEYO ‚ ® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
2023-05-22 07:00U:BCRXNews ReleaseBioCryst Announces Approval of ORLADEYO ‚ ® (berotralstat) by the Public Health Institute of Chile